Sanofi Genzyme is proud of our long history in Pompe disease and equally proud of the long history of working with the Pompe community to meet the needs of patients. Research and development in Pompe disease at Sanofi Genzyme started in 1988 and reached an important milestone in 2006 with the approval of the first treatment for Pompe disease that has changed outcomes for people living with Pompe disease around the world. In 2006, we established our humanitarian program, which has helped patients from more than 65 countries. Today, we continue to study this disease with the hope of finding better solutions, motivated by the goal to further improve the lives of our patients.
Through the years working with patients in the Pompe community, we understand that the journey to diagnosis, while getting better for many, can still be a long and winding path for far too many people. We are inspired by patient stories, such as Sean and Cheryl’s, which communicates a powerful story about the importance of family testing. At Sanofi Genzyme, we continue to innovate our ways of working with and supporting the Pompe community. It is a team effort involving industry, patients, patient groups, and healthcare practitioners to increase efforts to identify, diagnose and appropriately manage patients.
Even in tough times, we are working hard and hand-in-hand with the community to ensure patients get the support they need. Our hope for the future, is one in which we carry on efforts to help Pompe patients get to an earlier diagnosis, and pioneer new solutions for Pompe patients, their families and caregivers, because every patient counts.
MAT-GL- 2000316 04/2020
No comments:
Post a Comment